Search

Displaying results 4171 - 4180 of 10000 in total
  1. Drug

    Noberastine

    go.drugbank.com/drugs/DB20429
    Experimental

    The usage of the INN stem '-astine' in the name indicates that Noberastine is a antihistaminic. Noberastine has a monoisotopic molecular weight of 311.17 Da.

  2. Drug

    Levosemotiadil

    go.drugbank.com/drugs/DB20446
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Levosemotiadil is a vasodilator. Levosemotiadil has a monoisotopic molecular weight of 536.2 Da.

  3. Drug

    Ipramidil

    go.drugbank.com/drugs/DB20454
    Experimental

    The usage of the INN stem '-dil' in the name indicates that Ipramidil is a vasodilator. Ipramidil has a monoisotopic molecular weight of 256.12 Da.

  4. Drug

    Pexantel

    go.drugbank.com/drugs/DB20771
    Experimental

    The usage of the INN stem '-antel' in the name indicates that Pexantel is a anthelminthic. Pexantel has a monoisotopic molecular weight of 210.17 Da.

  5. Drug

    Zilantel

    go.drugbank.com/drugs/DB20793
    Experimental

    The usage of the INN stem '-antel' in the name indicates that Zilantel is a anthelminthic. Zilantel has a monoisotopic molecular weight of 664.11 Da.

  6. Drug

    Bepiastine

    go.drugbank.com/drugs/DB19791
    Experimental

    The usage of the INN stem '-astine' in the name indicates that Bepiastine is a antihistaminic. Bepiastine has a monoisotopic molecular weight of 299.11 Da.

  7. Drug

    Haloprogesterone

    go.drugbank.com/drugs/DB20259
    Experimental

    The usage of the INN stem '-terone' in the name indicates that Haloprogesterone is a antiandrogen. Haloprogesterone has a monoisotopic molecular weight of 410.13 Da.

  8. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  9. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848]

  10. Drug

    Lucinactant

    go.drugbank.com/drugs/DB04897
    Approved

    Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use.